Publication | Open Access

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

MedicineGynecologyCancer GenomicsRecurrent Endometrial CancerPotential Prognostic ValueCancer GeneticsEgfr MutationsOncologyRadiation Oncology